Development and validation of a urinary microRNA biomarker panel as a tool for early detection of prostate cancer in a Chinese population

References

• Adams, B.D., Kasinski, A.L., and Slack, F.J., 2014. Aberrant regulation and function of microRNAs in cancer. Current biology: CB, 24 (16), R762–R776.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. (2022). Cancer Facts & Figures. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf [Accessed 2 May 2022]
   Google Scholar
• Batra, J.S., Girdhani, S., and Hlatky, L., 2014. A quest to identify prostate cancer circulating biomarkers with a bench-to-bedside potential. Journal of biomarkers, 2014, 321680.
   PubMedGoogle Scholar
• Brase, J.C., et al., 2011. Circulating miRNAs are correlated with tumor progression in prostate cancer. International journal of cancer, 128 (3), 608–616.
   PubMed Web of Science ®Google Scholar
• Brawer, M.K., 1999. Prostate-specific antigen: current status. CA: a cancer journal for clinicians, 49 (5), 264–281.
   PubMed Web of Science ®Google Scholar
• Bryant, R.J., et al., 2012. Changes in circulating microRNA levels associated with prostate cancer. British journal of cancer, 106 (4), 768–774.
   PubMed Web of Science ®Google Scholar
• Chen, Z.H., et al., 2012. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. The prostate, 72 (13), 1443–1452.
   PubMed Web of Science ®Google Scholar
• Coradduzza, D., et al., 2022a. Plasma polyamine biomarker panels: agmatine in support of prostate cancer diagnosis. Biomolecules, 12 (4), 514.
   PubMed Web of Science ®Google Scholar
• Coradduzza, D., et al., 2022b. miRNAs as molecular biomarkers for prostate cancer. The journal of molecular diagnostics: JMD, 24 (11), 1171–1180.
   PubMed Web of Science ®Google Scholar
• Crawford, E.D., et al., 1999. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. The prostate, 38 (4), 296–302.
   PubMed Web of Science ®Google Scholar
• Daniel, R., et al., 2017. A panel of MicroRNAs as diagnostic biomarkers for the identification of prostate cancer. International journal of molecular sciences, 18 (6), 1281.
   PubMed Web of Science ®Google Scholar
• Descotes, J.-L., 2019. Diagnosis of prostate cancer. Asian journal of urology, 6 (2), 129–136.
   PubMed Web of Science ®Google Scholar
• Fabris, L., et al., 2016. The potential of microRNAs as prostate cancer biomarkers. European urology, 70 (2), 312–322.
   PubMed Web of Science ®Google Scholar
• Haj-Ahmad, T.A., Abdalla, M.A., and Haj-Ahmad, Y., 2014. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. Journal of cancer, 5 (3), 182–191.
   PubMed Web of Science ®Google Scholar
• Haldrup, C., et al., 2014. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug delivery and translational research, 4 (1), 19–30.
   PubMed Web of Science ®Google Scholar
• Hong, L.Z., et al., 2021. Systematic evaluation of multiple qPCR platforms, nanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids. Scientific reports, 11, 1–11.
   PubMed Web of Science ®Google Scholar
• Kachakova, D., et al., 2015. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. NA and cell biolodgy, 34 (3), 189–200.
   Google Scholar
• Korzeniewski, N., et al., 2015. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urologic oncology, 33 (1), 16.e17–16.e22.
   PubMed Web of Science ®Google Scholar
• Kretschmer, A., and Tilki, D., 2017. Biomarkers in prostate cancer - current clinical utility and future perspectives. Critical reviews in oncology/hematology, 120, 180–193.
   PubMed Web of Science ®Google Scholar
• Labbé, M., et al., 2020. microRNAs identified in prostate cancer: correlative studies on response to ionizing radiation. Molecular cancer, 19 (1), 1–18.
   PubMed Web of Science ®Google Scholar
• Lekchnov, E.A., et al., 2018. Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. International journal of molecular sciences, 19 (12), 4088.
   PubMed Web of Science ®Google Scholar
• Lyu, J., et al., 2019. Discovery and validation of serum micrornas as early diagnostic biomarkers for prostate cancer in Chinese population. BioMed research international, 2019, 9306803.
   PubMed Web of Science ®Google Scholar
• Manceau, C., On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française dU., et al., 2021. Biomarker in active surveillance for prostate cancer: a systematic review. Cancers (cancers), 13 (17), 4251.
   PubMed Web of Science ®Google Scholar
• Matin, F., Australian Prostate Cancer BioResource., et al., 2018. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer. Scientific reports, 8 (1), 15.
   PubMedGoogle Scholar
• Moltzahn, F., et al., 2011. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer research, 71 (2), 550–560.
   PubMed Web of Science ®Google Scholar
• Payne, S.R., et al., 2009. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. The prostate, 69 (12), 1257–1269.
   PubMed Web of Science ®Google Scholar
• Ramirez-Garrastacho, M., et al., 2022. Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients. British journal of cancer, 126 (3), 492–501.
   PubMed Web of Science ®Google Scholar
• Rawla, P., 2019. Epidemiology of prostate cancer. World journal of oncology, 10 (2), 63–89.
   PubMedGoogle Scholar
• Saini, S., 2016. PSA and beyond: alternative prostate cancer biomarkers. Cellular oncology, 39 (2), 97–106.
   PubMed Web of Science ®Google Scholar
• Strand, S.H., et al., 2020. Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific reports, 10 (1), 1–12.
   PubMed Web of Science ®Google Scholar
• Stuopelyte, K., et al., 2016. The utility of urine-circulating miRNAs for detection of prostate cancer. British journal of cancer, 115 (6), 707–715.
   PubMed Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71 (3), 209–249.
   PubMed Web of Science ®Google Scholar
• Thompson, I.M., et al., 2005. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Jama, 294 (1), 66–70. Jr.
   PubMed Web of Science ®Google Scholar
• Tsukerman, P., et al., 2014. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget, 5 (23), 12141–12150.
   PubMedGoogle Scholar
• Valera, V.A., et al., 2020. microRNA expression profiling in young prostate cancer patients. Journal of cancer, 11 (14), 4106–4114.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2016. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Molecular cancer, 15 (1), 1–11.
   PubMedGoogle Scholar
• Xu, B., et al., 2015. Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. The prostate, 75 (16), 1896–1903.
   PubMed Web of Science ®Google Scholar
• Yaman Agaoglu, F., et al., 2011. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour biology: the journal of the international society for oncodevelopmental biology and medicine, 32 (3), 583–588.
   PubMed Web of Science ®Google Scholar
• Zhao, J., et al., 2020. miR-31-5p regulates 14-3-3 ɛ to inhibit prostate cancer 22RV1 cell survival and proliferation via PI3K/AKT/Bcl-2 signaling pathway. Cancer management and research, 12, 6679–6694.
   PubMed Web of Science ®Google Scholar
• Zhao, Z., et al., 2021. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition. British journal of cancer, 124 (5), 982–994.
   PubMed Web of Science ®Google Scholar